Osagie Obasogie and Marcy Darnovsky’s Beyond Bioethics: Toward a New Biopolitics
By Travis Chi Wing Lau,
Somatosphere [review of the book edited by CGS' Osagie K Obasogie and Marcy Darnovsky]
| 09. 13. 2018
“The science will let loose its cascading interactions with utter impassivity; yet how we inhabit that knowledge will be a contest of the imagination, a sedimentation of political futures, a constructed infinity of worlds.” —Patricia J. Williams
What are the consequences of a bioethics that fails to keep up? With the rapid development of new biotechnologies like CRISPR, Beyond Bioethics makes a timely call for a novel take on bioethics capable of addressing the significant sociopolitical implications of these technologies. The contributors to this volume make clear that triumphalist cultural narratives of scientific innovation and progress have obfuscated and even impeded necessary ethical conversations about the development and application of biotechnologies too often touted as the future of biomedicine. Each of the 54 essays in this collection demonstrates how current bioethical frameworks and vocabularies fail to effectively grapple with the complex, intersectional problems that come with assisted reproduction or human genetic modification. Bridging together thinkers across the humanities and sciences divide, Beyond Bioethics models a progressive, interdisciplinary approach to bioethics that extends beyond a focus on the individual toward...
Related Articles
By Rob Stein, NPR [cites CGS' Katie Hasson] | 08.06.2025
A Chinese scientist horrified the world in 2018 when he revealed he had secretly engineered the birth of the world's first gene-edited babies.
His work was reviled as reckless and unethical because, among other reasons, gene-editing was so new...
By John H. Evans, Craig Callender, Neal K. Devaraj, Farren J. Isaacs, and Gregory E. Kaebnick, Issues in Science and Technology | 07.04.2025
The controversy around a ban on “mirror life” should lead to a more nuanced public conversation about how to manage the benefits and risks of precursor biotechnologies.
About five years ago, the five of us formed a discussion group to...
By Geoffrey A. Fowler, The Washington Post | 07.17.2025
Nearly 2 million people protected their privacy by deleting their DNA from 23andMe after it declared bankruptcy in March. Now it’s back with the same person in charge — and I still don’t trust it.
Nor do the attorneys general...
By Angus Liu, Fierce Pharma | 07.22.2025
A brief skirmish between Sarepta Therapeutics and the FDA has ended before escalating into a full-on regulatory clash, as the company has bowed to the agency’s demand.
In a surprising reversal, Sarepta on Monday said it will pause all shipments...